The improvement rate is 68%! Remdesivir's clinical results announced for severely ill patients with new coronary

On June 11, the New England Journal of Medicine published the results of sympathetic medication spent in patients with Reedsywe Covid-19, showing that 36 (68%) of the 53 patients hospitalized with severe COVID-19 and received Reedsy's sympathetic drug were observed to have clinical benefitsThe efficacy judgment is subject to the results of a randomized, placebo-controlled trial of Redsiwe, which is currently being implemented (funded by Gilead Sciences)The paper notes that Redsivir was provided to patients hospitalized with COVID-19 (caused by SARS-CoV-2 infection) who were treated with sympathetic medicationThe patients were confirmed to be infected with SARS-CoV-2, who had an oxygen saturation of 94% or oxygen support when breathing ambient airPatients receive Redseve treatment for 10 days, the program for the first day of intravenous administration 200 mg, in the following 9 days of daily administration of 100 mgThe study notes that the patient queue data are based on clinical data from Redsewe treatment between January 25, 2020 and March 7, 2020, and at least one followingThe results showed that 61 patients received at least one Redsiwe treatment, of which 8 patients had data that could not be analyzed (7 patients lacked data after treatment and 1 patient was given incorrect administration)Data for 53 patients were analyzed, including 22 in the United States, 22 in Europe or Canada and 9 in JapanAt baseline, 30 patients (57%) were receiving mechanical ventilation treatment and 4 (8%) were receiving in vitro membrane oxygenationThe median follow-up time was 18 days, during which 36 patients (68%) had improved oxygen support grading, of which 17 (57%) of the 30 patients with mechanical ventilation support had the trachea intubation removedA total of 25 patients (47 per cent) were discharged from hospital and 7 (13 per cent) died, while among patients receiving invasive ventilation, the mortality rate was 18 per cent (6 out of 34), while the mortality rate was 5 per cent (1 death out of 19 patients) who did not receive invasive ventilationIt was therefore concluded that 36 (68%) of the 53 patients hospitalized for severe COVID-19 and received Redsewe's sympathetic medication observed clinical benefitsThe efficacy judgment is subject to the results of a randomized, placebo-controlled trial of Redsiwe, which is currently being implemented (funded by Gilead Sciences)The following is the original text of the study: